Advertisement

C-reactive protein predicts death in patients with previous premature myocardial infarction—A 10 year follow-up study

      Abstract

      Atherosclerosis is an inflammatory disease. C-reactive protein (CRP), a marker of inflammation, is associated with coronary heart disease (CHD). We measured CRP in a cohort of 247 patients (193 males and 54 females) who had had their first myocardial infarction (MI) at age ≤55 (males) or ≤60 (females). The cut-off values of the 25th, 50th and 75th centiles of CRP were 1.20, 2.37 and 4.20 mg/l. After 10 years, a total of 44 patients (17.8%) had died, 36 (81.8%) of cardiac causes. Unadjusted and adjusted (i.e. for age, ejection fraction (EF), serum total cholesterol (TC), fibrinogen, smoking and hypertension) relative risks (RRs) for total and cardiac mortality were generated. CRP was a strong predictor of death of all causes due to its strength as predictor of cardiac death. The RR of cardiac death was doubled with increasing CRP quartiles, and patients in the top quartile had six times as high risk of cardiac death as patients in the lowest quartile. The RRs were moderately attenuated after adjustment, but still significant. We conclude that CRP is a strong predictor of mortality in patients with premature MI. Thus, inflammation appears to be a critical prognostic factor in patients with previous premature MI.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ross R.
        Atherosclerosis—an inflammatory disease.
        New Engl. J. Med. 1999; 340: 115-126
        • Liuzzo G.
        • Biasucci L.M.
        • Gallimore J.R.
        • Grillo R.L.
        • Rebuzzi A.G.
        • Pepys M.B.
        • Maseri A.
        The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
        New Engl. J. Med. 1994; 331: 417-424
        • Pietila K.O.
        • Harmoinen A.P.
        • Jokiniitty J.
        • Pasternack A.I.
        Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment.
        Eur. Heart J. 1996; 17: 1345-1349
        • Muir K.W.
        • Weir C.J.
        • Alwan W.
        • Squire I.B.
        • Lees K.R.
        C-reactive protein and outcome after ischemic stroke.
        Stroke. 1999; 30: 981-985
        • Ridker P.M.
        • Cushman M.
        • Stampfer M.J.
        • Tracy R.P.
        • Hennekens C.H.
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        New Engl. J. Med. 1997; 336: 973-979
        • Koenig W.
        • Sund M.
        • Frohlich M.
        • Fischer H.G.
        • Lowel H.
        • Doring A.
        • Hutchinson W.L.
        • Pepys M.B.
        C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study 1984–1992.
        Circulation. 1999; 99: 237-242
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        New Engl. J. Med. 2000; 342: 836-843
        • Bohn M.
        • Berge K.E.
        • Bakken A.
        • Erikssen J.
        • Berg K.
        Insertion/deletion (I/D) polymorphism at the locus for angiotensin I- converting enzyme and myocardial infarction.
        Clin. Genet. 1993; 44: 292-297
      1. Thompson GR, Wilson P. Coronary Risk Factors and Their Assessment. London: Science Press, 1992. p. 7.1–7.10.

        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499-502
        • Clauss A.
        Gerinnungs-physiologische Schnellmetode zur Bestimmung des Fibrinogens.
        Acta Haematol. 1957; 17: 237-246
        • Holm B.
        • Godal H.C.
        • Kierulf P.
        Does qualitatively altered fibrinogen contribute to the increased heparin precipitable fraction (HPF) in acute myocardial infarction (AMI)?.
        Thromb. Res. 1984; 33: 9-18
        • Berg K.
        • Kierulf P.
        DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration.
        Clin. Genet. 1989; 36: 229-235
        • Eda S.
        • Kaufmann J.
        • Roos W.
        • Pohl S.
        Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range.
        J. Clin. Lab. Anal. 1998; 12: 137-144
        • Mangschau A.
        • Karlsen R.L.
        • Lippestad C.T.
        • Nerdrum H.J.
        Systolic time intervals and ejection fraction in assessing left ventricular performance following acute myocardial infarction. Comparison of systolic time intervals and equilibrium radionuclide ventriculography.
        Acta Med. Scand. 1984; 215: 341-347
        • Haverkate F.
        • Thompson S.G.
        • Pyke S.D.
        • Gallimore J.R.
        • Pepys M.B.
        Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
        Lancet. 1997; 349: 462-466
        • Pepys M.B.
        • Baltz M.L.
        Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.
        Adv. Immunol. 1983; 34: 141-212
        • Baumann H.
        • Gauldie J.
        The acute phase response.
        Immunol. Today. 1994; 15: 74-80
        • Pietila K.
        • Harmoinen A.
        • Poyhonen L.
        • Koskinen M.
        • Heikkila J.
        • Ruosteenoja R.
        Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction.
        Br. Heart J. 1987; 58: 225-229
        • Lagrand W.K.
        • Visser C.A.
        • Hermens W.T.
        • Niessen H.W.
        • Verheugt F.W.
        • Wolbink G.J.
        • Hack C.E.
        C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?.
        Circulation. 1999; 100: 96-102
        • Danesh J.
        • Whincup P.
        • Walker M.
        • et al.
        Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.
        Br. Med. J. 2000; 321: 199-204
        • Lonn E.M.
        • Yusuf S.
        Evidence based cardiology: emerging approaches in preventing cardiovascular disease.
        Br. Med. J. 1999; 318: 1337-1341
        • McGhie A.I.
        • Willerson J.T.
        • Corbett J.R.
        Radionuclide assessment of ventricular function and risk stratification after myocardial infarction.
        Circulation. 1991; 84: I167-I176
        • Meade T.W.
        • Mellows S.
        • Brozovic M.
        • et al.
        Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.
        Lancet. 1986; 2: 533-537
        • Thompson S.G.
        • Kienast J.
        • Pyke S.D.
        • Haverkate F.
        • van de Loo J.C.
        Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
        New Engl. J. Med. 1995; 332: 635-641
        • Woodward M.
        • Lowe G.D.
        • Rumley A.
        • Tunstall-Pedoe H.
        Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.
        Eur. Heart J. 1998; 19: 55-62
        • Ernst E.
        • Resch K.L.
        Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.
        Ann. Intern. Med. 1993; 118: 956-963
      2. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-enzyme inhibitor, ramipril, on cardivascular events in high-risk patients. New Engl J Med 2000; 342:145–153.

        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • Sacks F.
        • Braunwald E.
        Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
        Circulation. 1999; 100: 230-235